Aquinox Pharmaceuticals to Announce Second Quarter 2017 Financial Results
August 01 2017 - 9:15AM
Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a
clinical-stage pharmaceutical company discovering and developing
targeted therapeutics in disease areas of inflammation and
immuno-oncology, will report its financial results for the second
quarter ending June 30, 2017 and will provide a general business
update on Tuesday, August 8, 2017 before U.S. markets open.
Aquinox’s management will also host a conference call and live
audio webcast on Tuesday, August 8, 2017 at 8:30 AM (ET) / 5:30 AM
(PT).
Conference Call and Webcast
Details:Date: Tuesday, August 8th, 2017Time: 8:30 AM (ET)
/ 5:30 AM (PT)Toll-free: (866) 357-7878International: (315)
625-3088Conference ID: 59711876Webcast URL:
http://edge.media-server.com/m/p/mqa4bkna
The live webcast may be accessed through the
"Events & Presentations" page in the "Investor Relations"
section of the company's website at www.aqxpharma.com.
The archived webcast will also be available on
Aquinox's website approximately two hours after the event and will
be available for replay for at least 30 days after the event.
About Aquinox
Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a late
clinical-stage pharmaceutical company discovering and developing
targeted therapeutics in disease areas of inflammation and
immuno-oncology. Our primary focus is anti-inflammatory product
candidates targeting SH2-containing inositol-5'-phosphatase 1, or
SHIP1, which is a key regulator of an important cellular signaling
pathway in immune cells, known as the PI3K pathway. Aquinox's lead
drug candidate, AQX-1125, is a small molecule activator of SHIP1
suitable for oral, once daily dosing. In September 2016, we began
enrolling patients in a Phase 3 clinical trial of AQX-1125 in our
lead indication, Interstitial Cystitis/Bladder Pain Syndrome
(IC/BPS). Other indications are under consideration for future
investigation. Aquinox has a broad intellectual property portfolio
and pipeline of preclinical drug candidates that activate SHIP1.
For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan
PayneAssociate Director, Investor
Relations Aquinox Pharmaceuticals,
Inc.604.901.3019ir@aqxpharma.com |
Gitanjali Ogawa Vice
President The Trout
Group646-378-2949Gogawa@troutgroup.com |
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
From Apr 2024 to May 2024
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
From May 2023 to May 2024